Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: A pharmacodynamic study of onset of action and efficacy

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 151-157

  Horak, Friedrich ^a,d   Zieglmayer, Ursula Petra ^a   Zieglmayer, René ^b   Kavina, Alexander ^b   Marschall, Kristina ^c   Munzel, Ullrich ^c   Petzold, Ursula ^c  

^a University Clinic Vienna   (Austria)

^b Allergy Centre Vienna West   (Austria)

^c Viatris Inc   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Azelastine nasal spray; Desloratadine tablets; Environmental exposure unit; Grass pollen challenge; Vienna Challenge Chamber

Indexed keywords

ALLERGEN; AZELASTINE; DESLORATADINE; NOSE SPRAY; PLACEBO; SALBUTAMOL;

ADULT; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED LUNG FUNCTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRASS POLLEN; HAY FEVER; HUMAN; LUNG FUNCTION; MAJOR NASAL SYMPTOM SCORE; MALE; NOSE CONGESTION; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; TABLET FORMULATION; TOTAL NASAL SYMPTOM SCORE; VIENNA CHALLENGE CHAMBER;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; PHTHALAZINES; POLLEN; RHINITIS, ALLERGIC, SEASONAL; TABLETS; TREATMENT OUTCOME;

EID: 30844450124     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80305     Document Type: Article

References (16)

1. Grossman J. One airway, one disease. Chest 1997;111(2):S11-6
2. McTavish D, Sorkin EM. Azelastine - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989;38(5):778-800
3. McNeely W, Wiseman LR. Intranasal azelastine - a review of its efficacy in the management of allergic rhinitis. Drugs 1998;56(1):91-114
4. McClellan K, Jarvis B. Desloratadine. Drugs 2001;61(6):789-96
5. Horak F, Jäger S. The Vienna Challenge Chamber - a new method of allergen exposition test. Wien Klin Wochenschr 1987;99(14):509-10
6. Day JH, Briscoe MP. Environmental exposure unit: a system to test anti-allergic treatment. Ann Allergy Asthma Immunol 1999;83:83-93
7. Horak F, Stübner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125:73-9
8. Horak F, Stübner UP, Zieglmayer R, et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109(6):956-61
9. Murdoch D, Goa KL, Keam SJ. Desloratadine - an update of its efficacy in the management of allergic disorders. Drugs 2003;63(19):2051-77
10. Thomas KE, Ollier S, Ferguson H, et al. The effect of intranasal azelastine, Rhinolast®, on nasal airway obstruction and sneezing following provocation testing with histamine and allergen. Clin Exp Allergy 1992;22:642-7
11. Horak F, Jäger S, Toth J, et al. Azelastine in pollen-induced allergic rhinitis - a pharmacodynamic study of onset of action and efficacy. Drug Invest 1994;7(1):34-40
12. Baumgarten CR, Petzold U, Dokic D, et al. Modification of allergen-induced symptoms and mediator release by intranasal azelastine. J Pharmacol Ther 1994;3(2):43-51
13. Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996;98(6):1088-96
14. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allerg Asthma Immunol 1998;81:478-518
15. Horak F, Stübner UP, Zieglmayer R, et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis [Abstract 1000]. Allergy 2000;55(63):S279
16. Horak F, Stübner P. Decongestant activity of desloratadine in controlled-allergen-exposure trials. Clin Drug Invest 2002;22(Suppl 2):13-20